Bingo! [Two-Stage / GS Designs]

posted by jatkins_5 – Philippines, 2014-10-30 04:53 (3902 d 20:32 ago) – Posting: # 13814
Views: 9,048

An option would be to use EMA’s approach of “leaving one out”; you would get only the pooled variance of the remaining pair.


Good day sirs!

In the above quote, is it statistically valid to establish ANOVA using drugs A and B only (as if done like a 2-way 2-seq crossover) in stage 1 (Potvin Method C) even though the study was done on a 3-way 6-seq crossover (Williams design) with drugs A, B and C? (asssuming the protocol specifically states that sequential BE shall be done on drugs A and B only; drug C shall be done for descriptive statistics determination only). Also, may I ask what specific EMA guideline mentioned the above approach so I could explore the topic further. I know a lot of discussion has already been poured on sequential BE, but I couldn't find a specific answer to my query. Many thanks in advance!

jerry

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,679 registered users;
30 visitors (0 registered, 30 guests [including 10 identified bots]).
Forum time: 02:26 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5